EHAB
Enhabit, Inc. NYSE$13.74
Mkt Cap $703.8M
52w Low $6.47
93.8% of range
52w High $14.22
50d MA $13.68
200d MA $9.95
P/E (TTM)
-151.8x
EV/EBITDA
10.7x
P/B
1.2x
Debt/Equity
0.9x
ROE
-0.9%
P/FCF
7.1x
RSI (14)
—
ATR (14)
—
Beta
1.08
50d MA
$13.68
200d MA
$9.95
Avg Volume
1.5M
About
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, A…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | AMC | 0.14 | 0.14 | +0.0% | 13.61 | -0.1% | +0.0% | +0.0% | +0.4% | -0.1% | +0.1% | — |
| Nov 5, 2025 | AMC | 0.12 | 0.17 | +41.7% | 8.21 | +2.9% | -6.1% | -3.2% | -3.4% | -2.7% | -1.9% | — |
| Aug 6, 2025 | AMC | 0.10 | 0.13 | +30.0% | 6.77 | +4.1% | +15.2% | +12.6% | +7.5% | +11.4% | +11.8% | — |
| May 7, 2025 | AMC | 0.07 | 0.10 | +42.9% | 8.20 | +5.6% | +18.2% | +25.4% | +27.6% | +27.7% | +29.0% | — |
| Mar 5, 2025 | AMC | 0.07 | 0.04 | -42.9% | 8.54 | -8.8% | -6.1% | -0.1% | +1.5% | -1.1% | +0.0% | — |
| Nov 6, 2024 | AMC | 0.04 | 0.03 | -21.1% | 7.91 | -2.5% | +0.1% | -0.3% | +1.3% | -3.8% | -3.8% | — |
| Aug 6, 2024 | AMC | 0.06 | 0.07 | +16.7% | 9.89 | -5.2% | -14.1% | -13.9% | -14.5% | -17.4% | -10.9% | — |
| May 8, 2024 | AMC | 0.05 | 0.07 | +40.0% | 9.70 | -22.1% | -14.5% | -14.0% | -10.9% | -6.8% | -10.7% | — |
| Mar 6, 2024 | AMC | 0.03 | 0.06 | +128.0% | 7.86 | +20.0% | +22.1% | +31.6% | +25.8% | +32.6% | +37.9% | — |
| Nov 7, 2023 | AMC | 0.06 | 0.03 | -48.3% | 8.55 | +0.2% | +16.0% | +10.3% | +8.8% | +7.6% | +14.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6 | TD Cowen | Downgrade | Buy → Hold | — | $13.61 | $13.60 | -0.1% | +0.0% | +0.4% | -0.1% | +0.1% | +0.0% |
| Feb 24 | UBS | Downgrade | Buy → Neutral | — | $13.60 | $13.59 | -0.1% | -0.3% | -0.1% | +0.0% | +0.1% | -0.1% |
| Feb 23 | Jefferies | Downgrade | Buy → Hold | — | $11.09 | $13.58 | +22.5% | +22.6% | +22.3% | +22.5% | +22.6% | +22.7% |
| Feb 23 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $11.09 | $13.58 | +22.5% | +22.6% | +22.3% | +22.5% | +22.6% | +22.7% |
| Jan 22 | Oppenheimer | Upgrade | Perform → Outperform | — | $10.74 | $11.10 | +3.4% | +3.1% | +0.5% | -0.1% | -3.4% | -3.9% |
| Jan 13 | TD Cowen | Upgrade | Hold → Buy | — | $10.19 | $11.11 | +9.0% | +7.5% | +6.0% | +6.9% | +3.2% | +2.4% |
| Jan 8 | UBS | Upgrade | Neutral → Buy | — | $9.51 | $10.04 | +5.6% | +7.2% | +4.8% | +7.2% | +15.1% | +13.6% |
| Aug 8 | UBS | Maintains | Neutral → Neutral | — | $7.80 | $7.72 | -1.0% | -2.3% | -6.7% | -3.3% | -2.9% | -5.3% |
| Dec 9 | Jefferies | Upgrade | Hold → Buy | — | $7.73 | $8.17 | +5.7% | +13.2% | +11.1% | +10.3% | +10.2% | +10.2% |
| Nov 19 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $7.14 | $7.05 | -1.3% | +1.8% | +4.5% | +4.6% | +5.9% | +6.7% |
Recent Filings
8-K
Enhabit, Inc. -- 8-K Filing
Enhabit faces shareholder lawsuits challenging disclosures in its proxy statement regarding management financial projections and Goldman Sachs valuation analyses, creating potential litigation risk and liability exposure.
May 5
8-K
Unknown — 8-K Filing
The merger is progressing on schedule with regulatory approval secured, suggesting the deal will close in Q2 2026 as planned, reducing execution risk for shareholders awaiting the transaction completion.
Apr 16
8-K · 7.01
! Medium
Enhabit, Inc. -- 8-K 7.01: Regulation FD Disclosure
Enhabit disclosed material non-public information to select parties, potentially creating information asymmetry and raising concerns about fair market access to critical company updates for all shareholders.
Mar 5
8-K · 1.01
! Medium
Enhabit, Inc. -- 8-K 1.01: Financing / Debt Agreement
Enhabit secured a five-year credit facility with SOFR-based variable interest rates, providing flexible financing for operations while exposing the company to interest rate fluctuations.
Mar 4
8-K · 5.02
!!! Very High
Enhabit, Inc. -- 8-K 5.02: Executive Change
Enhabit appointed Ryan Solomon as Chief Financial Officer, replacing Collin McQuiddy who resigned as Senior Vice President, signaling potential leadership transition that could impact financial strategy execution.
Feb 27
8-K
Enhabit, Inc. -- 8-K Filing
Enhabit's merger agreement cancels out-of-the-money employee stock options while preserving in-the-money options and RSUs, diluting existing shareholders through the equity consideration structure of the transaction.
Feb 23
8-K · 7.01
! Medium
Enhabit, Inc. -- 8-K 7.01: Regulation FD Disclosure
Enhabit disclosed material information to select parties under Regulation FD, signaling potential market-moving news that all investors should now have access to through this filing.
Feb 12
Data updated apr 25, 2026 6:41am
· Source: massive.com